Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
GenFleet Therapeutics (Shanghai) 14-Day RSI Related Terms
HAM:Y3L vs VRTX, REGN, RVMD: 14-Day RSI Comparison
For the Biotechnology subindustry, GenFleet Therapeutics (Shanghai)'s 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GenFleet Therapeutics (Shanghai) 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GenFleet Therapeutics (Shanghai)'s 14-Day RSI distribution charts can be found below:
* The bar in red indicates where GenFleet Therapeutics (Shanghai)'s 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a 14-Day RSI of 35.77 as of Aug. 04, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. According to the industry distribution chart, GenFleet Therapeutics (Shanghai) ranks #231 out of 1422 companies in the Biotechnology industry, placing it in the top 16.2%.
Is GenFleet Therapeutics (Shanghai)'s 14-Day RSI too high?
GenFleet Therapeutics (Shanghai)'s current 14-Day RSI is 35.77. The Biotechnology industry median 14-Day RSI is 45.28. GenFleet Therapeutics (Shanghai)'s value of 35.77 is 21% below this industry median. Based on the distribution chart, GenFleet Therapeutics (Shanghai) ranks #231 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, GenFleet Therapeutics (Shanghai) has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does GenFleet Therapeutics (Shanghai)'s 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GenFleet Therapeutics (Shanghai) ranks #231 out of 1422 companies for 14-Day RSI. This places GenFleet Therapeutics (Shanghai) in the top 16% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 45.28. GenFleet Therapeutics (Shanghai)'s value of 35.77 is 21% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 45.28, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GenFleet Therapeutics (Shanghai)'s current 14-Day RSI of 35.77 is 21% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. For the Biotechnology industry, the median 14-Day RSI is 45.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GenFleet Therapeutics (Shanghai)'s current 14-Day RSI is 35.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenFleet Therapeutics (Shanghai) stock overvalued right now?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a current 14-Day RSI of 35.77. The current 14-Day RSI is 35.77 and 21% below the Biotechnology industry median of 45.28. GenFleet Therapeutics (Shanghai)'s overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For GenFleet Therapeutics (Shanghai) (HAM:Y3L), the current 14-Day RSI is 35.77 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment.
19GF Score
Get the complete analysis for HAM:Y3L
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:Y3L has been successfully added to your 
